The United States diabetes drugs market grows with rising diabetes prevalence, improved access to healthcare, and advancements in treatment options. Demand increases for insulin, oral antidiabetic drugs, and innovative therapies such as GLP-1 agonists, driven by better disease management awareness and strong pharmaceutical R&D pipelines. https://www.imarcgroup.com/united-states-diabetes-drugs-market